ArticleCurrent oncology (Toronto, Ont.)2015

An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT.

C T Kouroukis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.